5-MeO-DMT
5-methoxy-N,N-dimethyltryptamine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) — known as "the toad" — is a short-acting psychedelic of the tryptamine class. It is a close structural relative of DMT, but far more potent. It activates serotonin receptors in the brain,[1] producing an almost instantaneous dissolution of self and identity.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DMT, psilocybin, LSD +1 moreDMT, psilocybin, LSD, mescaline show less
First synthesized in 1936, 5-MeO-DMT was later found in multiple plant species and in the parotoid gland secretions of the Sonoran Desert toad (Incilius alvarius).[2] Toad-venom smoking brought the compound to wider attention in the 1980s,[3] and underground ceremonial use expanded through the 2000s. Active clinical programs now investigate it as a treatment for depression, with recent trials showing high remission rates.[4]
Subjective effects include rapid ego dissolution, mystical states, intense emotional enhancement, and somatic overwhelm.[5] The experience is defined less by what is seen than by what disappears — self-boundaries collapse into undifferentiated unity, with far less visual complexity than DMT or psilocybin.[5] Intense fear, panic, confusion, and overwhelming disorientation are common.[6]
5-MeO-DMT produces no physical dependence and has no confirmed lethal dose in humans.[5] The principal danger is pharmacokinetic: blood levels rise disproportionately with dose increases,[7] and combining it with monoamine oxidase inhibitors multiplies exposure several times over, producing dangerous overheating and seizures.[8] Clinical investigation is accelerating, but published human pharmacokinetic data remain unavailable as of April 2026.
History[edit]
Discovery
First synthesized by Toshio Hoshino and Kenya Shimodaira in 1936,[2] 5-MeO-DMT predates LSD by seven years. It was later found in multiple plant species and in the parotoid gland secretions of the Sonoran Desert toad (Incilius alvarius).[3] Albert Most's 1984 pamphlet publicized the toad connection and brought the compound to broader public attention.
Clinical significance
Clinical programs began in earnest in the 2020s. GH Research's vaporized formulation progressed through Phase 2b trials for treatment-resistant depression, showing 57.7% remission at Day 8 and 77.8% at six months.[4][9] Beckley Psytech and the Usona Institute are developing separate formulations.[10][11]
Scheduling
The United States placed 5-MeO-DMT in Schedule I in January 2011.[12] Sweden classified it as a health hazard in 2004, among the first jurisdictions to act.[13] The compound remains unscheduled internationally, and legal retreat programs operate in Mexico and other jurisdictions.
The name 5-MeO-DMT follows standard tryptamine shorthand: "5-MeO" denotes the methoxy group at the 5-position of the indole ring, and "DMT" abbreviates dimethyltryptamine. In underground use, the compound is frequently called "the toad" or "toad venom" — a reference to its presence in the secretions of Incilius alvarius, though synthetic material now dominates supply. The toad association has generated conservation concerns, as wild harvesting of I. alvarius populations has intensified alongside growing interest in the compound.
Chemistry[edit]
Structural class
5-MeO-DMT belongs to the substituted tryptamine family — the same chemical scaffold shared by DMT, psilocin, and the neurotransmitter serotonin. The 5-methoxy substitution on the indole ring distinguishes it from both DMT and the 4-substituted psilocybin family.
The body converts a portion of it to bufotenine (5-hydroxy-DMT) through liver metabolism,[14] and it occurs naturally in several plant species and in the secretions of the Sonoran Desert toad.[3]
Molecular structure
| Molecular formula | C₁₃H₁₈N₂O |
| Molecular weight | 218.29 g/mol |
Pharmacology[edit]
Mechanism of action
5-MeO-DMT activates serotonin receptors in the brain, producing its psychedelic effects primarily through one receptor type while a second moderates and shortens the experience.[1][15] This second receptor also contributes the anxiolytic and antidepressant properties being studied clinically.[1] The dual-receptor action sets it apart from LSD and psilocybin, which act more selectively on one serotonin receptor type.
Pharmacokinetics
The body breaks 5-MeO-DMT down rapidly through enzymatic breakdown — the main reason effects last only minutes.[16][14][7] A secondary liver enzyme converts a portion to bufotenine, an active metabolite; how much is produced varies by genetics, and some people metabolize it far less efficiently.[8][17]
At higher doses, blood levels rise far more than the dose increase would predict — 1.5 to 2.7 times higher.[7] Monoamine oxidase inhibitors block the main elimination pathway, multiplying blood levels 3.6 to 4.4 times and producing dangerous overheating.[8][18][19]
Neuroscience[edit]
Where it acts
5-MeO-DMT engages the same core brain systems as other serotonergic psychedelics, but simultaneous activation of a second serotonin receptor type introduces a moderating effect.[1] This is likely why the experience produces intense ego dissolution with relatively little visual content. No brain imaging studies in humans have been published.
Following the experience, salivary stress hormones and inflammation markers drop,[20] suggesting the compound reduces both stress responses and inflammation. How this connects to its therapeutic effects is not yet established.
Why it matters
One influential theory holds that psychedelics loosen the brain's top-down predictions, letting new emotional and sensory patterns take hold.[21] 5-MeO-DMT's rapid, complete ego dissolution fits this model — and the durability of clinical remission (77.8% at six months from a single session[4]) suggests lasting brain changes.
Whether 5-MeO-DMT triggers the same long-term brain rewiring as longer-acting psychedelics has not been tested. The most clinically relevant open question is whether the second serotonin receptor contributes independently to antidepressant effects[22] or merely makes the experience more tolerable — an answer that could determine whether 5-MeO-DMT holds inherent advantages over other psychedelics.
Subjective Effects[edit]
The 5-MeO-DMT experience is defined less by what is seen than by what disappears. Self-boundaries dissolve rapidly into an undifferentiated state of awareness — not a visual journey, but a total suspension of personal identity.[5] Somatic overwhelm and emotional enhancement are central rather than peripheral.
Among short-acting psychedelics, the closest comparison is DMT — but they diverge sharply. DMT builds elaborate visual worlds; 5-MeO-DMT strips them away, channeling intensity into the dissolution of self.[5] The degree of ego dissolution at typical doses exceeds what most people report from psilocybin or LSD.[1]
Effect Grid
Common doses produce the characteristic 5-MeO-DMT experience: rapid and intense ego dissolution, powerful emotional amplification across the full valence spectrum (bliss, awe, fear, surrender), and a sense of unity or oceanic boundlessness. Visual effects are present but notably less elaborate than other classical psychedelics — diffuse white light, geometric simplifications, and spatial distortions predominate over complex patterning.
Physically, significant increases in heart rate and blood pressure occur transiently. Nausea, muscle tension, trembling, and vocalization are common. Time distortion is profound — minutes may feel like hours or be entirely absent from awareness. Functional impairment is complete during the peak.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Proprioceptive distortion · Brightness alteration · Visual haze / noise · Light sensitivity · Color suppression · Touch enhancement · Perspective distortion · Sound sensitivity · Music enhancement · Auditory suppression · Visual acuity suppression · Geometry · Auditory distortion · Depth perception distortion · Touch suppression · Visual drifting · Color alteration · Synesthesia · Visual morphing · Visual breathing · Color enhancement · Tinnitus · Auditory misinterpretation · Tracers · Visual melting · After-images · Environmental patterning · Symmetrical texture repetition · Visual diffraction · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · Visual recursion · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Persisting hallucinations
Color suppression · Touch enhancement · Perspective distortion · Sound sensitivity · Music enhancement · Auditory suppression · Visual acuity suppression · Geometry · Auditory distortion · Depth perception distortion · Touch suppression · Visual drifting · Color alteration · Synesthesia · Visual morphing · Visual breathing · Color enhancement · Tinnitus · Auditory misinterpretation · Tracers · Visual melting · After-images · Environmental patterning · Symmetrical texture repetition · Visual diffraction · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · Visual recursion · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Persisting hallucinations
Pupil dilation · Vibrations / buzzing · Tingling / electric sensations · Stimulation · Body high · Involuntary body movements · Dizziness · Kundalini-like energy · Physical fatigue · Wakefulness · Excessive sweating · Breathing alteration · Heart rate perception changes · Sedation · Tactile euphoria · Bodily heaviness · Bodily pressures · Muscle tension · Nausea · Trembling · Bodily lightness · Muscle relaxation · Restlessness · Respiratory stimulation · Nasal congestion · Pain suppression · Sexual arousal suppression · Yawning · Vomiting · Salivation · Laughter fits · Nystagmus (eye wobbles) · Headache · Dry mouth · Insomnia · Respiratory depression · Watery eyes · Bruxism · Bodily dissociation · Tactile hallucination
Stimulation · Body high · Involuntary body movements · Dizziness · Kundalini-like energy · Physical fatigue · Wakefulness · Excessive sweating · Breathing alteration · Heart rate perception changes · Sedation · Tactile euphoria · Bodily heaviness · Bodily pressures · Muscle tension · Nausea · Trembling · Bodily lightness · Muscle relaxation · Restlessness · Respiratory stimulation · Nasal congestion · Pain suppression · Sexual arousal suppression · Yawning · Vomiting · Salivation · Laughter fits · Nystagmus (eye wobbles) · Headache · Dry mouth · Insomnia · Watery eyes · Bruxism · Bodily dissociation · Tactile hallucination
Memory suppression · Thought disorganization · Analysis suppression · Language suppression · Focus suppression · Memory fragmentation · Openness enhancement · Cognitive euphoria · Introspection enhancement · Novelty enhancement · Cognitive fatigue · Increased nature relatedness · Confusion · Thought connectivity · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Thought deceleration · Aesthetic enhancement · Thought acceleration · Creativity enhancement · Pattern recognition enhancement · Thought loops · Multiple thought streams · Synchronicity · Aesthetic suppression · Creativity suppression · Memory replays · Analysis enhancement · Amnesia · Delusions · Delirium
Language suppression · Focus suppression · Memory fragmentation · Openness enhancement · Cognitive euphoria · Introspection enhancement · Novelty enhancement · Cognitive fatigue · Increased nature relatedness · Confusion · Thought connectivity · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Thought deceleration · Aesthetic enhancement · Thought acceleration · Creativity enhancement · Pattern recognition enhancement · Thought loops · Multiple thought streams · Synchronicity · Aesthetic suppression · Creativity suppression · Memory replays · Analysis enhancement · Delusions · Delirium
Catharsis · Euphoria · Empathy enhancement · Anxiety suppression · Dysphoria
Dysphoria
Communication suppression · Sociability suppression · Disinhibition · Trust enhancement · Social connection · Compulsive behavior reduction · Flow state · Automaticity · Ego dissolution · Boundary dissolution · Cognitive disconnection · Identity alteration · Telepathic feelings
Social connection · Compulsive behavior reduction · Flow state · Automaticity · Ego dissolution · Boundary dissolution · Cognitive disconnection · Identity alteration · Telepathic feelings
Time cessation
Non-dual awareness · Voidness · Death-rebirth sequence · Near-death experience · Transpersonal visions · Entity contact · Transpersonal memory access
Transpersonal visions · Entity contact · Transpersonal memory access
Lucidity enhancement · Recursive awareness
Timeline
First effects emerge 1-10 minutes after insufflation — nasal burning or discomfort, followed by a gradual shift in headspace and emerging body sensations. Onset is markedly slower than vaporized administration.
Effects build progressively over 5-15 minutes. Body load increases with warmth, nausea, and muscle tension. Emotional sensitivity heightens and ego boundaries begin to soften.
Peak intensity sustained for 10-40 minutes. Ego dissolution, emotional amplification, and mystical-type states emerge with similar quality to vaporized administration but evolve more gradually. Visual effects remain subdued relative to other psychedelics.
A sustained plateau of moderate intensity follows the peak. Emotional processing, introspection, and residual perceptual shifts continue. Body awareness fluctuates between comfortable warmth and mild discomfort.
Gradual return to baseline over 30-60 minutes. Cognitive clarity returns progressively. Emotional sensitivity persists but perceptual distortions fade.
Residual mood changes, emotional openness, and enhanced introspection may persist for 1-4 hours. Nasal congestion or irritation from insufflation may linger. Mild fatigue is common.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 2 hours
- Physical
- None
- Psychological
- None
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DMT · psilo · LSD
Toxicity
Acute toxicity
No confirmed deaths from 5-MeO-DMT alone appear in national toxicology registries.[5] The human lethal dose is unknown. At very high exposures, tryptamine intoxication can produce loss of coordination, tremor, seizures, and respiratory failure.[23]
Heart and circulation
Heart rate and blood pressure rise during the acute experience.[9] In clinical trials these changes were transient, and 97.4% of patients were discharge-ready within one hour.[4]
Breathing
5-MeO-DMT can suppress breathing by inhibiting brainstem respiratory neurons, as demonstrated in animal models.[24] No respiratory problems were reported in published clinical trials, but this effect has not been evaluated at uncontrolled doses.
Overheating
5-MeO-DMT raises body temperature at higher doses. Combining it with monoamine oxidase inhibitors dramatically amplifies this — both serotonin receptor pathways simultaneously push body temperature upward, producing a potentially life-threatening overheating response.[19]
Nonlinear dose-response
Blood levels rise disproportionately with dose increases because metabolic pathways become saturated.[7] A moderate-to-high dose increase may produce 1.5 to 2.7 times the expected blood level increase, making precise dosing critical.
Psychological risks
The most common challenging effects are intense fear, panic, confusion, and overwhelming ego dissolution.[6][5] Acute distress scales with dose and is heavily influenced by setting. Retrospective data suggest psychotic reactions in roughly 10% of cases,[5] though dose variability and pre-existing vulnerability complicate this figure.
A minority of users report lasting effects — flashbacks, insomnia, and persistent anxiety.[6] Rare cases of HPPD (HPPD — recurring perceptual disturbances after the drug has cleared) appear in retrospective data.[23] Structured, supportive settings significantly reduce challenging experiences and improve outcomes.[25]
Tolerance & Dependence
Tolerance builds rapidly after a single dose through receptor internalization — the brain temporarily reduces receptor availability in response to activation.[26] Cross-tolerance with other classical psychedelics is expected.
5-MeO-DMT produces no physical dependence. Compulsive use has not been documented.[6]
Drug Interactions
MAO inhibitors (dangerous)
Combining 5-MeO-DMT with MAO inhibitors is the most dangerous interaction. Harmaline co-administration increases 5-MeO-DMT blood levels 3.6 to 4.4 times and bufotenine levels 6 to 10 times,[8][18] producing dangerous overheating, seizures, and cardiovascular instability.[19][27] This applies to beta-carboline alkaloids (harmaline, harmine, ayahuasca), pharmaceutical MAOIs, and reversible MAO-A inhibitors such as moclobemide.
SSRIs and serotonergic antidepressants
Interaction data are limited.[28] A 2026 proof-of-concept trial showed intranasal 5-MeO-DMT can be given alongside SSRIs under medical supervision with acceptable safety.[29] Chronic SSRI use may reduce psychedelic response by decreasing serotonin receptor availability.
Tramadol
Tramadol has weak MAO-inhibiting activity and blocks serotonin reuptake. The combined serotonergic load with 5-MeO-DMT could trigger an overheating and seizure response. No specific interaction data exist.inferred
Stimulants (cocaine)
Cocaine raises monoamine levels and adds cardiovascular stress. Combined with 5-MeO-DMT's cardiovascular effects, the risk is plausible. No interaction data exist.inferred
Lithium
Lithium combined with serotonergic psychedelics is associated with seizure risk. No 5-MeO-DMT-specific data exist, but the interaction is flagged based on class evidence.inferred
CYP2D6 inhibitors
Drugs that inhibit the liver enzyme CYP2D6 — including fluoxetine, paroxetine, bupropion, and quinidine — could reduce bufotenine formation and alter the experience's character. This is mechanistically predicted but not experimentally confirmed.[27]
Contraindications
Concurrent MAOI use is an absolute contraindication outside controlled clinical settings. The 3.6 to 4.4-fold exposure increase and documented overheating risk[8][19] place this combination in the highest-risk category.
Personal or family history of psychotic disorders is a relative contraindication consistent with all classical psychedelics. The speed and intensity of ego dissolution may elevate risk of psychotic decompensation.
Heart conditions warrant caution given documented increases in heart rate and blood pressure.[9]
Breathing difficulties are a theoretical contraindication based on demonstrated respiratory suppression in animal models.[24]
Pregnancy and breastfeeding are contraindicated in the absence of reproductive safety data.
Harm Reduction[edit]
Forms & Identification
5-MeO-DMT circulates as freebase powder (for vaporization), crystalline material, and occasionally as dried toad secretion — each form carrying different challenges for accurate dosing.
Reagent testing confirms the presence of an indole-containing tryptamine but cannot distinguish 5-MeO-DMT from closely related compounds like DMT or bufotenine. Quantitative testing such as HPLC is the only reliable method for confirming identity and purity.
Toad-derived material carries additional risk — cardiac steroids (bufotoxins) are present alongside 5-MeO-DMT and pose a toxicity risk that reagent kits cannot detect. Synthetic material eliminates this concern entirely.
Guidelines
- Test material before use. Reagent testing confirms tryptamine class; quantitative analysis confirms identity and purity. Appearance alone is not reliable.
- Use a precision milligram scale. Nonlinear pharmacokinetics mean small dose errors produce disproportionate effects.[7] Eyeballing doses is dangerous with this compound.
- Start with a low dose. Genetic variation in liver metabolism affects sensitivity significantly[17] — individual response is unpredictable without prior experience.
- Have an experienced sitter present. Onset is too rapid and ego dissolution too complete for unsupervised first experiences.
- Fast for at least 4 hours beforehand. Nausea and vomiting can occur; aspiration risk increases when combined with loss of motor control.
- Prepare the physical space. Remove sharp objects and hard edges. Use a padded surface. Involuntary movement during the experience is common.
- Allow full recovery time before standing. Disorientation can persist 15–30 minutes after the acute experience resolves. Do not drive or operate equipment for several hours.
Set & Setting
The quality of a 5-MeO-DMT experience is unusually sensitive to context. Structured, supportive environments produce significantly higher rates of complete mystical experiences (83% vs 54%) and substantially lower challenging-experience scores.[25]
When vaporized, full effects arrive within seconds — there is no gradual entry period. A safe physical space and a trusted, experienced sitter are strongly recommended.
The sitter should be prepared for intense physical responses — involuntary movement, vocalization — and should understand that verbal reassurance may not reach the person at peak dissolution.
Aftercare & integration. The 5-MeO-DMT experience — particularly at ego-dissolving doses — can be profoundly disorienting even when subjectively positive. The brevity of the acute phase does not reflect the psychological weight of the experience.
Allow the remainder of the day for quiet recovery. Journaling within the first few hours captures impressions that fade quickly. Avoid major life decisions in the days immediately following — the sense of clarity the experience produces benefits from reflection before action.
Integration — making meaning from the experience — may benefit from professional support, particularly if the experience was distressing. Persistent anxiety, intrusive memories, or sleep disturbances lasting more than two weeks warrant professional evaluation.
Recovery & Support
5-MeO-DMT does not produce physical dependence, and compulsive use patterns are not documented. Repeated ceremonial use driven by a desire to recapture the experience's intensity can indicate patterns that benefit from honest self-assessment.
If psychedelic use is causing distress, interfering with daily functioning, or being used to avoid underlying issues, professional support is recommended. The Fireside Project (62-FIRESIDE) offers a psychedelic peer support line, and integration therapists can help process difficult or recurring experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Most 5-MeO-DMT experiences involve intense but transient distress that resolves without intervention. Seek emergency help if any of the following occur:
- Seizure or convulsions
- Breathing stops or becomes very slow
- Loss of consciousness that persists after the acute phase should have ended
- Rigid muscles with high body temperature (signs of serotonin syndrome — especially if MAOIs were involved)
- Self-harm behavior or attempts to flee into unsafe environments
Immediate steps:
- 1. Call emergency services if any of the above signs are present.
- 2. Place the person in the recovery position if unconscious but breathing.
- 3. Do not restrain the person unless they are in immediate physical danger.
- 4. Monitor breathing continuously. If breathing stops and you are trained, begin rescue breathing.
- 5. Keep the environment calm and quiet. Reduce stimulation.
What to tell the dispatcher:
State that the person has used a psychedelic tryptamine, the approximate amount and time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug-related emergencies.
Legal Status[edit]
5-MeO-DMT is not listed in the United Nations Convention on Psychotropic Substances — countries without domestic legislation have no international obligation to control it.[13]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Effective January 19, 2011; includes salts, isomers, and salts of isomers[12] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Illegal to possess, supply, or manufacture without license[13] |
| Canada | Not explicitly scheduled | Not listed under the Controlled Drugs and Substances Act; analog provisions may apply[13] |
| Australia | Controlled substance | Illegal to use, possess, or supply[13] |
| Sweden | Health hazard classification | Controlled since October 2004[13] |
| China | Controlled substance | Added to controlled list October 2015[13] |
| Mexico | Not controlled | No domestic scheduling; legal retreat programs operatecitation needed |
Legal status changes frequently and varies significantly by jurisdiction. This information is not legal advice.
references
- [1]
- [2]
- [3] ^abcWeil AT, Davis W (1994) Bufo alvarius: a potent hallucinogen of animal origin — Journal of Ethnopharmacology PMID:8170151
- [4]
- [5]
- [6] ^abcdDavis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption — Journal of Psychopharmacology doi:10.1177/0269881118769063